Evidence map›Paper›PMID 33790139›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy.

Yudai Fujiwara, Kazuyuki Suzuki, Kenji Yusa, Makoto Eizuka, Manami Miura, Yuki Watanabe, Hiroshi Takahashi, Yasuhiro Takikawa

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yudai FujiwaraDivision of Hepatology, Department of Internal Medicine, Iwate Medical University, Japan.
Kazuyuki SuzukiDivision of Hepatology, Department of Internal Medicine, Iwate Medical University, Japan.
Kenji YusaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University, Japan.
Makoto EizukaDepartment of Gastroenterology, Iwate Prefectural Ninohe Hospital, Japan.
Manami MiuraDepartment of Gastroenterology, Iwate Prefectural Ninohe Hospital, Japan.
Yuki WatanabeDivision of Hepatology, Department of Internal Medicine, Iwate Medical University, Japan.
Hiroshi TakahashiDepartment of Gastroenterology, Iwate Prefectural Ninohe Hospital, Japan.
Yasuhiro TakikawaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University, Japan.
Iwate Prefectural Central Hospital · JPIwate Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The patient was a 65-year-old man with alcoholic liver cirrhosis who had been admitted to hospital 5 times for repeated and recurrent overt hepatic encephalopathy (HE) despite numerous therapies, including disaccharide, branched-chain amino acid (BCAA) formula, L-carnitine and zinc. After the additional administration of rifaximin (1,200 mg/day orally), his consciousness level was well controlled for 3 years without any adverse effects. The long-term administration of rifaximin may be useful and safe for managing recurrent overt HE, although the maintenance dosage and duration of rifaximin and safety should be evaluated in patients with ameliorated HE.

Indexed as

Hepatic EncephalopathyAgedAmino Acids, Branched-ChainHumansLiver CirrhosisLiver Cirrhosis, AlcoholicLong-Term CareMaleRifaximinAmino Acids, Branched-ChainRifaximinhyperammonemialiver cirrhosisovert hepatic encephalopathyrifaximin

Identifiers

PMID33790139
PMCPMC8079929
OpenAlexW3140207113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.